Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash & Equivalents (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Cash & Equivalents for 15 consecutive years, with $17.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 66.06% to $17.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.5 million through Dec 2025, down 66.06% year-over-year, with the annual reading at $17.5 million for FY2025, 66.06% down from the prior year.
  • Cash & Equivalents hit $17.5 million in Q4 2025 for Cardiff Oncology, up from $10.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $79.9 million in Q1 2025 to a low of $10.1 million in Q3 2025.
  • Historically, Cash & Equivalents has averaged $24.2 million across 5 years, with a median of $18.1 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: tumbled 90.88% in 2021 and later surged 328.23% in 2025.
  • Year by year, Cash & Equivalents stood at $11.9 million in 2021, then skyrocketed by 36.88% to $16.3 million in 2022, then soared by 32.47% to $21.7 million in 2023, then soared by 137.68% to $51.5 million in 2024, then crashed by 66.06% to $17.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for CRDF at $17.5 million in Q4 2025, $10.1 million in Q3 2025, and $71.0 million in Q2 2025.